What question did this study set out to answer?

This research aims to evaluate the effectiveness of post-transplant cyclophosphamide as a prophylactic treatment to prevent graft-versus-host disease in patients undergoing stem cell transplantation for acute leukemia.

March 5, 2026SHILAP Revista de lepidopterologíaOpen Access

Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis for matched related donor hematopoietic stem cell transplantation in acute leukemia: a systematic review and meta-analysis.

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the effectiveness of post-transplant cyclophosphamide as a prophylactic treatment to prevent graft-versus-host disease in patients undergoing stem cell transplantation for acute leukemia.
Conducted a systematic review and meta-analysis of studies published until April 2025.
Included 21 studies with a total of 10,860 patients who received matched related donor hematopoietic stem cell transplants.
Compared outcomes of post-transplant cyclophosphamide-based GVHD prophylaxis with calcineurin inhibitor-based regimens.
PTCy significantly reduced acute GVHD grades II-IV with an odds ratio of 0.54.
Chronic GVHD occurrence was also lower with PTCy, showing an odds ratio of 0.47.
GVHD-free/relapse-free survival improved with PTCy, displaying an odds ratio of 2.29.
Adverse events included delayed engraftment and cytomegalovirus reactivation in 29% of patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Systematic review finds post-transplant cyclophosphamide reduces graft-versus-host disease in acute leukemia patients, suggesting its standard use.

Cite This Study

Shahsavand et al. (2026) studied this question.

synapsesocial.com/papers/69a91f0ad6127c7a504c285c https://doi.org/10.1080/16078454.2026.2631227

View Full Paper

Ask AI

Bookmark

Implication

Systematic review finds post-transplant cyclophosphamide reduces graft-versus-host disease in acute leukemia patients, suggesting its standard use.

Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis for matched related donor hematopoietic stem cell transplantation in acute leukemia: a systematic review and meta-analysis.

Key Points

Discussion

Implication

Cite This Study

Post-transplant cyclophosphamide as graft-versus-host disease prophylaxis for matched related donor hematopoietic stem cell transplantation in acute leukemia: a systematic review and meta-analysis.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider